Efficient Genome-Wide First-Generation Phenotypic Screening System in Mice Using the Piggybac Transposon

Total Page:16

File Type:pdf, Size:1020Kb

Efficient Genome-Wide First-Generation Phenotypic Screening System in Mice Using the Piggybac Transposon Efficient genome-wide first-generation phenotypic screening system in mice using the piggyBac transposon Hao Changa,b,c,1, Yukun Pana,b,1,2, Sean Landrettea,b, Sheng Dinga,b, Dong Yanga,c, Lufang Liua,b, Lei Tiana,b, Hongyan Chaid, Peining Lid, Da-Ming Lia,b,c, and Tian Xua,b,c,3 aDepartment of Genetics, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, CT 06536; bHoward Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06536; cSchool of Life Sciences, Westlake Institute for Advanced Study, Westlake University, 310024 Hangzhou, China; and dLaboratory of Clinical Cytogenetics and Genomics, Department of Genetics, Yale School of Medicine, New Haven, CT 06536 Edited by Norbert Perrimon, Howard Hughes Medical Institute, Boston, MA, and approved August 1, 2019 (received for review April 18, 2019) Genome-wide phenotypic screens provide an unbiased way to tetranucleotide target sites, has been modified to generate a bi- identify genes involved in particular biological traits, and have nary transposon system for mammalian cells and mammals. The been widely used in lower model organisms. However, cost and system contains a nonautonomous PB transposon cassette to de- time have limited the utility of such screens to address biological liver the exogenous genes of interest flanked by the PB inverted and disease questions in mammals. Here we report a highly efficient repeat sequences, and a transgene expressing the PB transposase piggyBac (PB) transposon-based first-generation (F1) dominant enzyme (PBase) for inducing transposition in the germline. screening system in mice that enables an individual investigator to Transposition occurs when PBase binds to the inverted repeat se- conduct a genome-wide phenotypic screen within a year with fewer than 300 cages. The PB screening system uses visually trackable quences of the PB transposon, initiating excision and reintegration transposons to induce both gain- and loss-of-function mutations into another locus. The binary PB system can efficiently transpose and generates genome-wide distributed new insertions in more in mice and human cells (9). Somatic mutagenesis using multiple than 55% of F1 progeny. Using this system, we successfully con- copies of Sleeping beauty (SB)orPB transposons to generate GENETICS ducted a pilot F1 screen and identified 5 growth retardation muta- dominant mutations have facilitated cancer gene discovery (10– + tions. One of these mutants, a Six1/4PB/ mutant, revealed a role in 13), highlighting the potential to modify this strategy for germline milk intake behavior. The mutant animals exhibit abnormalities in mutagenesis. Indeed, an SB germline system has been developed nipple recognition and milk ingestion, as well as developmental for region-specific saturation screens (14). A comparable system defects in cranial nerves V, IX, and X. This PB F1 screening system for genome-wide mutagenesis is needed. The PB transposon has offers individual laboratories unprecedented opportunities to con- been shown to have higher jumping efficiency and less-severe local duct affordable genome-wide phenotypic screens for deciphering hopping than SB in cultured mouse ES cells (15), thus holding the genetic basis of mammalian biology and disease pathogenesis. promise for affordable genome-wide in vivo germline mutagenesis screens in mice. piggyBac transposon | genome-wide screen | growth retardation | six1 | six4 Significance enome-wide phenotypic screens in mammals are critical for identifying the genes and pathways that are essential for Genome-wide, phenotype-driven mutagenesis in animal models G ’ human health and altered in diseases, but costs associated with could provide an unbiased way to decode a gene s functions and the generation of mutant animals and mapping of mutations its role in diseases. Here we have generated a piggyBac (PB) limit the practicality of current approaches. Traditionally, mouse transposon-based first-generation (F1) dominant screening sys- mutants have been generated from embryonic stem (ES) cells tem in mice, which provides unprecedented opportunities to with specific genes knocked out by homologous recombination conduct a highly efficient and affordable genome-wide pheno- (1, 2). CRISPR/Cas9 is a faster and more efficient technology to typic screen for an individual investigator in a single laboratory. generate mutations in individual genes (3). However, both ap- Using this system, we carried out an F1 dominant screen for growth retardation and discovered 5 isolated mutants that carry proaches remain prohibitively expensive for generating and transposon insertions hitting the genes Rin2, Rbm39, Mll, Zeb2, maintaining genome-wide mouse mutant libraries for phenotypic + and Six1/4.TheSix1/4PB/ mutant animals exhibit abnormalities screening. In contrast to gene-by-gene approaches, chemical mu- in nipple recognition and milk ingestion during the breastfeed- tagens, such as ENU, randomly generate point mutations and are ing period and also exhibit cranial nerve defects. highly potent in mice (4). While recessive screens require a costly 3 generations of breeding, first-generation (F1) dominant screens Author contributions: H. Chang, Y.P., D.-M.L., and T.X. designed research; H. Chang, Y.P., directly assay the progeny of mutagenized animals, reducing cost S.D., L.L., L.T., and D.-M.L. performed research; H. Chang, Y.P., S.L., H. Chai, P.L., and D.-M.L. and time. Genome-scale ENU F1 screens have been conducted contributed new reagents/analytic tools; H. Chang, Y.P., D.Y., and T.X. analyzed data; and for gross morphological, neurological, and immunological defects. H. Chang, Y.P., and T.X. wrote the paper. Key regulatory genes involved in colorectal cancer and circadian The authors declare no conflict of interest. rhythm have also been identified in dominant screens in mice (5– This article is a PNAS Direct Submission. 8). However, ENU F1 screens are still limited by the costs asso- Published under the PNAS license. ciated with the back-crosses and sequencing required for map- 1H. Chang and Y.P. contributed equally to this work. ping mutations. Alternative approaches that make genome-wide 2Present address: Yeda Research Center for Model Organisms, Taizhou, 318000 Zhejiang, screens affordable to individual investigators are highly desirable. China. Transposon insertional mutagenesis is an attractive alternative 3To whom correspondence may be addressed. Email: [email protected]. approach for genome-wide phenotypic screens in mammals. The This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. DNA “cut and paste” piggyBac (PB) transposon from the cabbage 1073/pnas.1906354116/-/DCSupplemental. looper moth Trichoplusia ni, which favorably inserts at TTAA Published online August 26, 2019. www.pnas.org/cgi/doi/10.1073/pnas.1906354116 PNAS | September 10, 2019 | vol. 116 | no. 37 | 18507–18516 Downloaded by guest on September 26, 2021 Here, we developed a highly efficient F1 dominant screening we developed a mutagenic PB construct that includes 4 important system in mice. The new PB system utilizes multiple copies of features: 1) A strong promoter for gene overexpression that can be visually trackable transposons to generate genome-wide muta- conditionally regulated; 2) a terminator for disrupting transcrip- tions in 55.2% of F1 progeny. Therefore, we estimate that this tion; 3) a Katushka red fluorescent protein (Kat) transgene (16); system could allow individual laboratories to perform a genome- and 4) a codon-optimized luciferase gene (luc2) under the control wide phenotypic F1 screen in mice within a year and with 300 cages of a Ubiquitin C (UBC) promoter (Fig. 1A) (12), which is dis- in total. Using this system, we carried out an F1 dominant screen rupted by the insertion of the PB construct. When PBase is for growth retardation and identified both gain- and loss-of- expressed to mobilize PB for mutagenesis, the luc2 gene activity is function alleles. Both intrauterine growth retardation (IUGR) restored as the PB insertion is excised (SI Appendix, Fig. S2A). and postnatal growth retardation (PGR) phenotypes were ob- This construct, named PB[mut-Kat], can induce both gain- and served in the 5 isolated mutants that carry transposon insertions loss-of-function mutations, visually track mutants, and report hitting the endocytosis regulator Rin2, the steroid hormone re- mutagenesis activity. ceptor coactivator Rbm39, the histone methyltransferase Mll,and High mutagenesis efficiency is required for a cost-effective the homeobox transcriptional factors Zeb2 and Six1/4. Altogether, screening system. Mobilizing a single PB transposon in the mouse our work demonstrates the applicability of our system for cost and germline is not sufficient to support a genome-wide screen (9). time-effective phenotypic screens. Increasing the copy number of the mutagenic transposon could improve efficiency, while too many copies of the transposon could Results cause lethality and tumorigenesis (11, 12). We therefore generated Development of a Highly Efficient F1 Mutagenesis Screening System six different mouse lines with copy number of the PB[mut-Kat] in Mice. The F1 mutagenesis system was designed as a binary PB transposon ranging from 1 to 22 (SI Appendix, Table S1). In order system (Fig. 1): A founder line carrying nonautonomous PB trans- to identify a transgenic line able to induce mutations in the poson constructs and a Jump-Starter line carrying a PBase transgene germline without
Recommended publications
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • High Resolution Physical and Comparative Maps of Horse
    HIGH RESOLUTION PHYSICAL AND COMPARATIVE MAPS OF HORSE CHROMOSOMES 14 (ECA14) AND 21 (ECA21) A Thesis by GLENDA GOH Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE May 2005 Major Subject: Genetics HIGH RESOLUTION PHYSICAL AND COMPARATIVE MAPS OF HORSE CHROMOSOMES 14 (ECA14) AND 21 (ECA21) A Thesis by GLENDA GOH Submitted to Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Approved as to style and content by: _________________________ _________________________ Bhanu P. Chowdhary Loren C. Skow (Chair of Committee) (Member) _________________________ _________________________ James N. Derr James E. Womack (Member) (Member) _________________________ _________________________ Geoffrey Kapler Evelyn Tiffany-Castiglioni (Chair of Genetics Faculty) (Head of Department) May 2005 Major Subject: Genetics iii ABSTRACT High Resolution Physical and Comparative Maps of Horse Chromosomes 14 (ECA14) and 21 (ECA21). (May 2005) Glenda Goh, B.S. (Hons.), Flinders University of South Australia Chair of Advisory Committee: Dr. Bhanu P. Chowdhary In order to identify genes or markers responsible for economically important traits in the horse, the development of high resolution gene maps of individual equine chromosomes is essential. We herein report the construction of high resolution physically ordered radiation hybrid (RH) and comparative maps for horse chromosomes 14 and 21 (ECA14 and ECA21). These chromosomes predominantly share correspondence with human chromosome 5 (HSA5), though a small region on the proximal part of ECA21 corresponds to a ~5Mb region from the short arm of HSA19. The map for ECA14 consists of 128 markers (83 Type I and 45 Type II) and spans a total of 1828cR.Compared to this, the map of ECA21 is made up of 90 markers (64 Type I and 26 Type II), that segregate into two linkage groups spanning 278 and 760cR each.
    [Show full text]
  • Mai Muudatuntuu Ti on Man Mini
    MAIMUUDATUNTUU US009809854B2 TI ON MAN MINI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,809 ,854 B2 Crow et al. (45 ) Date of Patent : Nov . 7 , 2017 Whitehead et al. (2005 ) Variation in tissue - specific gene expression ( 54 ) BIOMARKERS FOR DISEASE ACTIVITY among natural populations. Genome Biology, 6 :R13 . * AND CLINICAL MANIFESTATIONS Villanueva et al. ( 2011 ) Netting Neutrophils Induce Endothelial SYSTEMIC LUPUS ERYTHEMATOSUS Damage , Infiltrate Tissues, and Expose Immunostimulatory Mol ecules in Systemic Lupus Erythematosus . The Journal of Immunol @(71 ) Applicant: NEW YORK SOCIETY FOR THE ogy , 187 : 538 - 552 . * RUPTURED AND CRIPPLED Bijl et al. (2001 ) Fas expression on peripheral blood lymphocytes in MAINTAINING THE HOSPITAL , systemic lupus erythematosus ( SLE ) : relation to lymphocyte acti vation and disease activity . Lupus, 10 :866 - 872 . * New York , NY (US ) Crow et al . (2003 ) Microarray analysis of gene expression in lupus. Arthritis Research and Therapy , 5 :279 - 287 . * @(72 ) Inventors : Mary K . Crow , New York , NY (US ) ; Baechler et al . ( 2003 ) Interferon - inducible gene expression signa Mikhail Olferiev , Mount Kisco , NY ture in peripheral blood cells of patients with severe lupus . PNAS , (US ) 100 ( 5 ) : 2610 - 2615. * GeneCards database entry for IFIT3 ( obtained from < http : / /www . ( 73 ) Assignee : NEW YORK SOCIETY FOR THE genecards. org /cgi - bin / carddisp .pl ? gene = IFIT3 > on May 26 , 2016 , RUPTURED AND CRIPPLED 15 pages ) . * Navarra et al. (2011 ) Efficacy and safety of belimumab in patients MAINTAINING THE HOSPITAL with active systemic lupus erythematosus : a randomised , placebo FOR SPECIAL SURGERY , New controlled , phase 3 trial . The Lancet , 377 :721 - 731. * York , NY (US ) Abramson et al . ( 1983 ) Arthritis Rheum .
    [Show full text]
  • Prioritizing Parkinson’S Disease Genes Using Population-Scale
    ARTICLE https://doi.org/10.1038/s41467-019-08912-9 OPEN Prioritizing Parkinson’s disease genes using population-scale transcriptomic data Yang I. Li1, Garrett Wong2, Jack Humphrey 3,4 & Towfique Raj2 Genome-wide association studies (GWAS) have identified over 41 susceptibility loci asso- ciated with Parkinson’s Disease (PD) but identifying putative causal genes and the underlying mechanisms remains challenging. Here, we leverage large-scale transcriptomic datasets to 1234567890():,; prioritize genes that are likely to affect PD by using a transcriptome-wide association study (TWAS) approach. Using this approach, we identify 66 gene associations whose predicted expression or splicing levels in dorsolateral prefrontal cortex (DLFPC) and peripheral monocytes are significantly associated with PD risk. We uncover many novel genes associated with PD but also novel mechanisms for known associations such as MAPT, for which we find that variation in exon 3 splicing explains the common genetic association. Genes identified in our analyses belong to the same or related pathways including lysosomal and innate immune function. Overall, our study provides a strong foundation for further mechanistic studies that will elucidate the molecular drivers of PD. 1 Section of Genetic Medicine, Department of Medicine, and Department of Human Genetics, University of Chicago, Chicago 60637 IL, USA. 2 Departments of Neuroscience, and Genetics and Genomic Sciences, Ronald M. Loeb Center for Alzheimer’s disease, Icahn School of Medicine at Mount Sinai, New York 10029 NY, USA. 3 UCL Genetics Institute, Gower Street, London WC1E 6BT, UK. 4 Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1E 6BT, UK. These authors contributed equally: Yang I.
    [Show full text]
  • Microrna Regulation During Neuroinflammation: from Junk DNA to a Phd Thesis
    microRNA regulation during neuroinflammation: from junk DNA to a PhD thesis Camille A. Juźwik A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy in Neurological Sciences Integrated Program in Neuroscience Department of Neurology and Neurosurgery - McGill University 3801 University Street - Montreal, QC, H3A 2B4, Canada March 2019 © Camille A. Juźwik, 2019 All rights reserved Table of Contents 1 Forward………..……………………………………………………………. 5 1.1 Abstract………………………………………………………………………....................... 5 1.2 Résumé………………………………………………………………………....................... 6 1.3 Acknowledgments…………………………………………………………......................... 8 1.4 Preface and Author Contributions.…...……………………………………………........... 10 1.5 List of Figures and Tables…………………………………………………........................ 12 1.6 List of Abbreviations…….…………………………………………………........................ 15 1.7 List of Publications...…………………………………………………………...................... 17 2 Chapter 1. Introduction…………………………………………………... 19 2.1 General Introduction………………………………………………………………………. 19 2.2 Multiple Sclerosis……..…………………………………………………………………… 22 2.2.1 White matter lesions: axonal pathology….…………………………….............................................................. 24 2.2.2 Gray matter lesions: soma pathology ……….................................................................................................. 25 2.2.3 Experimental autoimmune encephalomyelitis…………………………………….............................................. 27 2.2.4 Not all
    [Show full text]
  • Tumor-Associated NADH Oxidase (Tnox)-NAD+-Sirtuin 1 Axis Contributes to Oxaliplatin-Induced Apoptosis of Gastric Cancer Cells
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 9), pp: 15338-15348 Research Paper Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells Huei-Yu Chen1, Hsiao-Ling Cheng1, Yi-Hui Lee1, Tien-Ming Yuan1,2, Shi-Wen Chen2, You-Yu Lin1, Pin Ju Chueh1,3,4,5 1Institute of Biomedical Sciences, National Chung Hsing University, Taichung, 40227, Taiwan 2Department of Surgery, Feng-Yuan Hospital, Ministry of Health and Welfare, Taichung 42055, Taiwan 3Graduate Institute of Basic Medicine, China Medical University, Taichung, 40402, Taiwan 4Department of Medical Research, China Medical University Hospital, Taichung, 40402, Taiwan 5Department of Biotechnology, Asia University, Taichung, 41354, Taiwan Correspondence to: Pin Ju Chueh, email: [email protected] Keywords: apoptosis, deacetylase, oxaliplatin, tumor-associated NADH oxidase (tNOX or ENOX2), sirtuin 1 (SIRT1) Received: October 20, 2016 Accepted: January 09, 2017 Published: January 21, 2017 ABSTRACT Oxaliplatin belongs to the platinum-based drug family and has shown promise in cancer treatment. The major mechanism of action of platinum compounds is to form platinum–DNA adducts, leading to DNA damage and apoptosis. Accumulating evidence suggests that they might also target non-DNA molecules for their apoptotic activity. We explored the effects of oxaliplatin on a tumor-associated NADH oxidase (tNOX) in gastric cancer lines. In AGS cells, we found that the oxaliplatin-inhibited tNOX effectively attenuated the NAD+/NADH ratio and reduced the deacetylase activity of an NAD+-dependent sirtuin 1, thereby enhancing p53 acetylation and apoptosis. Similar results were also observed in tNOX-knockdown AGS cells.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Rabbit Anti-ZFYVE16/FITC Conjugated Antibody
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-ZFYVE16/FITC Conjugated antibody SL19157R-FITC Product Name: Anti-ZFYVE16/FITC Chinese Name: FITC标记的Zinc finger protein结构域ZFYVE16抗体 AI035632; B130024H06Rik; B130031L15; DKFZp686E13162; Endofin; Endosomal associated FYVE domain protein; Endosome associated FYVE domain protein; Endosome-associated FYVE domain protein; KIAA0305; KIAA0305;; mKIAA0305; Alias: OTTMUSP00000029589; RGD1564784; ZFY16_HUMAN; ZFYVE16; Zinc finger FYVE domain containing protein 16; Zinc finger FYVE domain-containing protein 16; Zinc finger, FYVE domain containing 16. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Pig,Cow,Horse,Rabbit,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 88kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLHwww.sunlongbiotech.com conjugated synthetic peptide derived from human ZFYVE16 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: This gene encodes an endosomal protein that belongs to the FYVE zinc finger family of Product Detail: proteins. The encoded protein is thought to regulate membrane trafficking in the endosome.
    [Show full text]
  • Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024
    Document downloaded from http://www.elsevier.es, day 26/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Nº Ref Uniprot Proteína Péptidos identificados 1 P01024 CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 por 162MS/MS 2 P02751 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 131 3 P01023 A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 128 4 P0C0L4 CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 95 5 P04275 VWF_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 81 6 P02675 FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 78 7 P01031 CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 66 8 P02768 ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 66 9 P00450 CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 64 10 P02671 FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 58 11 P08603 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 56 12 P02787 TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 54 13 P00747 PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 48 14 P02679 FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 47 15 P01871 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 16 P04003 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 37 17 Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 30 18 O43866 CD5L_HUMAN CD5 antigen-like OS=Homo
    [Show full text]
  • NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 11-7-2018 Decipher Mechanisms by which Nuclear Respiratory Factor One (NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer Jairo Ramos [email protected] Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Clinical Epidemiology Commons Recommended Citation Ramos, Jairo, "Decipher Mechanisms by which Nuclear Respiratory Factor One (NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer" (2018). FIU Electronic Theses and Dissertations. 3872. https://digitalcommons.fiu.edu/etd/3872 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida DECIPHER MECHANISMS BY WHICH NUCLEAR RESPIRATORY FACTOR ONE (NRF1) COORDINATES CHANGES IN THE TRANSCRIPTIONAL AND CHROMATIN LANDSCAPE AFFECTING DEVELOPMENT AND PROGRESSION OF INVASIVE BREAST CANCER A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in PUBLIC HEALTH by Jairo Ramos 2018 To: Dean Tomás R. Guilarte Robert Stempel College of Public Health and Social Work This dissertation, Written by Jairo Ramos, and entitled Decipher Mechanisms by Which Nuclear Respiratory Factor One (NRF1) Coordinates Changes in the Transcriptional and Chromatin Landscape Affecting Development and Progression of Invasive Breast Cancer, having been approved in respect to style and intellectual content, is referred to you for judgment.
    [Show full text]